Ad
related to: nivolumab and relatlimab rmbw- PH 3 Efficacy Results
Review the Clinical Trial Data for
A Combo Therapy Treatment Option.
- Clinical Guidelines
View Guidelines & Recommendations
For PADCEV®.
- HCP Resources
Download Resources for You and Your
Patient, See Support Information.
- Dosing & Administration
Understand the Dosing Instructions
and Modifications for PADCEV®.
- PH 3 Efficacy Results
Search results
Results from the WOW.Com Content Network
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. [10] It contains nivolumab , a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab , a lymphocyte activation gene-3 (LAG-3) blocking antibody. [ 10 ]
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. [3] [4] It is used in combination with nivolumab to treat melanoma. [2] [5] Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. [2] [5] It is under development by Bristol-Myers Squibb. [2] [5] It is made using Chinese hamster ovary cells. [2]
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...
Nivolumab/hyaluronidase, sold under the brand name Opdivo Qvantig, is a fixed-dose combination anti-cancer medication used for the treatment of various forms of cancer. [ 1 ] [ 2 ] Nivolumab/hyaluronidase contains nivolumab , a programmed death receptor-1 (PD-1)-blocking monoclonal antibody ; and hyaluronidase , an endoglycosidase . [ 1 ]
Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [ 16 ] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [ 17 ]
Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements. [1]
mRNA-4157/V940 is an mRNA based cancer vaccine encapsulated in solid lipid nanoparticles.The 34 mRNA sequences in mRNA-4157/V940 vaccine were generated by an automated algorithm integrated with workflow based on massive parallel sequencing of tissue generated from cancer patients. [1]
The US Food and Drug Administration (FDA) evaluated the safety and efficacy of retifanlimab based on PODIUM-201 (NCT03599713), an open-label, multiregional, single-arm study evaluating 65 participants with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for advanced disease.
Ad
related to: nivolumab and relatlimab rmbw